Free Trial

Argus' Rating of 10x Genomics on 9/28/2026

On September 28, 2026, Argus updated its outlook on 10x Genomics (NASDAQ:TXG) with the action "Initiated Coverage", setting a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Argus

DateCompanyAction
11/12/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Set Price Target
11/12/2026
Amgen Inc. stock logo
AMGN
Amgen
Boost Price Target
11/12/2026
Wayfair Inc. stock logo
W
Wayfair
Boost Price Target
11/12/2026
CoreWeave Inc. stock logo
CRWV
CoreWeave
Lower Price Target
11/12/2026
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
Boost Price Target
11/12/2026
Reddit Inc. stock logo
RDDT
Reddit
Lower Price Target
More Ratings From Argus